Beta-2-microglobulin as a uremic toxin: the Japanese experience.
Gejyo and coworkers identified β(2)-microglobulin (β(2)-MG) as the major constitutional protein of dialysis-related amyloidosis (DRA) a quarter of a century ago. Since then, β(2)-MG has been the most extensively studied low molecular weight protein in end-stage renal disease. The onset of DRA may be prevented by the use of high-flux dialysis membranes, especially when high-volume hemodiafiltration is used in the treatment of uremic patients. Adsorption therapy is another choice to improve the removal of β(2)-MG. There seems to be a relative risk reduction in mortality when patients are treated with dialysis membranes that have a higher clearance of β(2)-MG.